Narcolepsy

Drs Thorpy, Dogan, Doghramji, and Kushida share clinical pearls for primary care providers who are taking care of patients with narcolepsy.

Experts in sleep medicine the ongoing studies and new treatments for narcolepsy

Drs Thorpy, Dogan, Doghramji, and Kushida talk about treatment holidays in narcolepsy.

Alkermes embarks on the phase 2 Vibrance-1 trial to evaluate the safety and efficacy of ALKS 2680 against placebo as a once-daily treatment for narcolepsy type 1.

Experts in sleep medicine discuss the criteria for changing treatment in narcolepsy.

Alberto Ramos, MD, FAAN, director of the Sleep Disorders program at the University of Miami, provided commentary on a session chaired at AAN 2024 assessing the diagnostic criteria and treatment options of parasomnias in adults.

Drs Thorpy, Dogan, Doghramji, and Kushida talk about the use and uptake of newer narcolepsy treatments in clinical practice.

Experts in sleep medicine share their knowledge on abuse and dependency potential with newer narcolepsy treatment.

Sleep medicine experts discuss the treatment of narcolepsy in pregnancy.

Drs Thorpy, Bogan, Doghramji, and Kushida discuss combination therapy and patients with complex narcoleptic disease.

Drs Thorpy, Dogan, Doghramji, and Kushida detail which medications to use in various patients with narcolepsy.

Experts in sleep medicine summarize the available safety data on various agents for the treatment of narcolepsy.

Drs Thorpy, Dogan, Doghramji, and Kushida review the various treatment classes for narcolepsy.

Sleep medicine experts discuss how to select the appropriate treatment for narcolepsy.

ALKS 2680, an investigational orexin 2 receptor agonist, showed promise for improving sleep latency in patients with narcolepsy type 2 and idiopathic hypersomnia in a phase 1b study.

The newly initiated phase 3 trial follows a successful phase 2 study where treatment with pitolisant resulted in greater improvement on the Epworth Sleepiness Scale for Children and Adolescents than placebo.

The presence of a sleep disorder was associated with a nearly 2-fold increase in the risk of increased health care utilization, with specific odds associated with individual sleep disorders.

Experts in sleep medicine talk about the effect narcolepsy can have on the quality of life.

Sleep medicine experts review the contributing factors and comorbidities seen in patients with narcolepsy.

The medical director of the Center for Sleep Medicine at Weill Cornell Medicine talked about the importance of sleep health in modern life with the increasing prevalence of sleep disorders such as narcolepsy in the United States. [WATCH TIME: 5 minutes]

Sleeping Around the Podcast is joined by Rachel Nesmith, a patient with narcolepsy, who shares her story of overcoming the burdens and impairments of living with narcolepsy and cataplexy.

Drs Thorpy, Dogan, Doghramji, and Kushida discuss the frequency of symptoms encountered in patients who are diagnosed with narcolepsy.

Experts in sleep medicine discuss the clinical features of narcolepsy.

A meta-analysis on studies assessing FDA-approved dual orexin receptor antagonists for insomnia treatment highlighted a greater risk of adverse events, particularly for narcolepsy-like symptoms.

The director of the Comprehensive Epilepsy Center—Sleep Center at NYU Langone provided perspective on the overlap in characteristics of sleep disorders and the necessary approach to ensuring accurate diagnosis and initial treatment. [WATCH TIME: 5 minutes]

TAK-861, an orexin receptor 2 agonist, demonstrated efficacy and safety in a phase 2b trial for narcolepsy type 1.

The associate professor, department of medicine, division of neurology, Institute of Medical Science, University of Toronto, shared his thoughts on potential therapies and expanding care options for sleep disorders in 2024. [WATCH TIME: 5 minutes]

In a phase 2 proof-of-concept study, IHL-42X, a drug for obstructive sleep apnea, more significantly reduced apnea-hypopnea index and oxygen desaturation index than placebo.

Data supported a positive causal association between narcolepsy and schizophrenia and a reverse causal relationship between narcolepsy and major depressive disorder.

A recent open-label study focused on vagus nerve stimulation therapy's effects on patients with narcolepsy revealed a specific and notable improvement in daytime sleepiness.